Hong Kong-listed Sino Biopharmaceutical will sell a 67% stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the company said late on...
Novartis in the lead to acquire cancer drug developer MorphoSys – sources
Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said on Monday...
ADIA, HarbourVest eye minor stake in Cohance
The Abu Dhabi Investment Authority (ADIA), the sovereign wealth fund of the oil-rich emirate, along with London-based private equity fund HarbourVest, is in discussions to acquire a minority stake in Cohance...
India’s Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 mln
India’s Sun Pharmaceutical Industries Limited said on Wednesday it would buy all the shares of Taro Pharmaceutical Industries it does not already own for $43 per share in cash, effectively taking full control of...
Grifols says Haier Group still OK to buy stake in Shanghai RAAS
Spanish pharma company Grifols said Chinese home appliance maker Haier Group still plans to close the acquisition of a 20% stake in Shanghai RAAS Blood Products (002252.SZ) as announced in late December. Grifols...
Merck to buy Harpoon Therapeutics for $680 million
Merck & Co said it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies. The U.S. drugmaker has been doubling down on building future...
Dr Reddy’s acquires MenoLabs’ women health brands in US
Dr. Reddy’s on Wednesday acquired MenoLabs business, a leading women’s health and dietary supplement branded portfolio from Amyris through Chapter 11 bankruptcy proceeding in the US Bankruptcy Court for the...
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said it has agreed to buy LumiraDx’s Point of Care diagnostics platform business for about $295 million. Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction...
AstraZeneca to buy China’s Gracell Biotechnologies in $1.2 billion deal
AstraZeneca said it will buy Gracell Biotechnologies for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world’s second-largest...
Biocon weighs sale of $1.5 billion generic API business
Biocon is evaluating a plan to sell its generic active pharmaceutical ingredient (API) business – estimated to be worth $1.5 billion – to reduce its overall debt, though it is yet to take any concrete...
Sun Pharma revises upwards price to fully acquire Taro to USD 43 per share
Sun Pharmaceutical Industries said it has revised upwards the price at which it proposed to fully acquire Israel-based Taro Pharmaceutical Industries to USD 43 per share in cash. In May this year, the company announced...
AbbVie to buy drug developer Cerevel for $8.7 billion
AbbVie said it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition. It marks...
